SARS-CoV-2灭活疫苗对奥密克戎变异株突破性感染后症状的影响
研究基于疫苗接种后长期随访队列,通过问卷收集奥密克戎变异株突破性感染时的一般症状,并评估血浆特异性抗体(中和抗体、抗S IgG、抗N IgG)及T细胞应答。结果发现,感染前抗体水平更高、T细胞活化与应答更强的人,感染后症状更轻,尤其发热峰值温度更低。提示灭活疫苗诱导的细胞和体液免疫可能对突破性感染后的严重临床症状提供保护。
要点
- 感染前抗体水平更高者,突破性感染后症状更轻
- 感染前T细胞活化与应答更强,与症状较轻相关
- 发热峰值温度较低者,感染前抗体和T细胞应答更高
核心结论
- 灭活疫苗诱导的细胞免疫和体液免疫可能对奥密克戎变异株突破性感染后的严重临床症状提供保护。
研究设计与样本
- 基于疫苗接种后长期随访队列,采用问卷调查研究奥密克戎变异株突破性感染时的一般症状,并评估血浆特异性抗体(中和抗体、抗S IgG、抗N IgG)和T细胞应答。
主要发现
- 症状较轻者,尤其是发热峰值温度较低者,在感染前表现出更高的抗体水平和更强的T细胞活化与应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The SARS-CoV-2 Omicron variant and its sublineages continue to circulate widely. Clinical outcomes with this variant differ among individuals, primarily influenced by host immunity. Previous studies have explored the relationship between immune responses and severe diseases in infected or convalescent patients. However, the impact of vaccine-induced immune responses on disease severity, especially in cases of mild infection following breakthrough infection, remains unclear. This is primarily due to the lack of assessment of immune status in vaccinated individuals before infection. In this study, we aimed to elucidate the causality between virus-specific cellular and humoral immune responses and the severity of symptoms in breakthrough infected patients from a long-term follow-up post-vaccination cohort. A questionnaire survey was conducted to collect general symptoms upon breakthrough infection with the Omicron variants. Plasma levels of specific antibodies (neutralizing antibodies, anti-S IgG, and anti-N IgG) and T cell responses induced by inactivated SARS-CoV-2 vaccine were evaluated. The findings revealed that individuals with milder symptoms, particularly lower peak fever temperatures, exhibited higher antibody levels and enhanced T cell activation and responses prior to infection. This suggests that cellular and humoral immunity induced by inactivated vaccines may provide protection against severe clinical symptoms following breakthrough infection.
引用
- Zhang Y, Li X, Yang Y, et al. Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection. Vaccine. 2025. PMID: 39813973. doi:10.1016/j.vaccine.2025.126722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。